Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma – Reasons and consequences

Genes and Cancer

Volumn 5, Issue 1-2, 2015, Pages 56-63

  Arabi, Leila ^a,b   Gsponer, Joël R ^a   Smida, Jan ^c   Nathrath, Michaela ^c   Perrina, Valeria ^a   Jundt, Gernot ^a   Ruiz, Christian ^a   Quagliata, Luca ^a   Baumhoer, Daniel ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

BIM; FAS; miR 106a 363; miR 106b 25; miR 17 92; Osteosarcoma

Indexed keywords

BIM PROTEIN; FAS ANTIGEN; MICRORNA; MICRORNA 106B; MICRORNA 19B; MICRORNA 92A; MICRORNA 17; MICRORNA 17-92; MICRORNA 18A; MICRORNA 19A; MICRORNA 20A; MYC PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCHOOL CHILD; UPREGULATION; VERY ELDERLY;

EID: 84922718558     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Rosenberg AE, Cleton-Jansen A-M, de Pinieux G, Deyrup AT, Hauben E and Squire J. (2013). Conventional osteosarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F, eds. WHO Classification of Tumours of Tumours of Soft Tissue and Bone. (Lyon, France: IARC Press), pp. 282-288.
2. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H and Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20(3):776-790.
3. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Muller C, Tienghi A, Wiebe T, Comandone A, Bohling T, Del Prever AB, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005; 23(34):8845-8852.
4. Kong C and Hansen MF. Biomarkers in osteosarcoma. Expert Opin Med Diagn. 2009; 3(1):13-23.
5. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ and Hammond SM. A microRNA polycistron as a potential human oncogene. Nature. 2005; 435(7043):828-833.
6. Xiang J and Wu J. Feud or Friend? The Role of the miR- 17-92 Cluster in Tumorigenesis. Current genomics. 2010; 11(2):129-135.
7. Zhou M, Ma J, Chen S, Chen X and Yu X. MicroRNA-17-92 cluster regulates osteoblast proliferation and differentiation. Endocrine. 2013.
8. Li M, Guan X, Sun Y, Shu X and Li C. MiR-92a family and their target genes in tumorigenesis and metastasis. Exp Cell Res. 2014.
9. Mogilyansky E and Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013; 20(12):1603-1614.
10. Baumhoer D, Zillmer S, Unger K, Rosemann M, Atkinson MJ, Irmler M, Beckers J, Siggelkow H, von Luettichau I, Jundt G, Smida J and Nathrath M. MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma. Cancer Genet. 2012; 205(5):212-219.
11. Namløs HM, Meza-Zepeda LA, Baroy T, Ostensen IH, Kresse SH, Kuijjer ML, Serra M, Burger H, Cleton-Jansen AM and Myklebost O. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One. 2012; 7(10):e48086.
12. Yang J and Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013; 25(4):398-406.
13. Huang G, Nishimoto K, Zhou Z, Hughes D and Kleinerman ES. MiR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res. 2012; 72(4):908-916.
14. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402-408.
15. R Core Team. (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
16. Venables WN and Ripley BD. (2002). Modern Applied Statistics with S: Springer, New York.
17. Hothorn T, Hornik K, van de Wiel MA and Zeileis A. A Lego System for Conditional Inference. The American Statistician. 2006; 60(3):257-263.
18. Therneau TM. (2013). A Package for Survival Analysis in S. R package version 2.37-4. URL http://CRAN.R-project.org/package=survival.
19. Therneau TM and Grambsch PM. (2000). Modeling Survival Data: Extending the Cox Model: Springer, New York.
20. Olive V, Li Q and He L. Mir-17-92: a polycistronic oncomir with pleiotropic functions. Immunol Rev. 2013; 253(1):158-166.
21. Smida J, Baumhoer D, Rosemann M, Walch A, Bielack S, Poremba C, Remberger K, Korsching E, Scheurlen W, Dierkes C, Burdach S, Jundt G, Atkinson MJ and Nathrath M. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res. 2010; 16(16):4256-4267.
22. Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, Quan L, Bai J and Xu N. MiR-106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. Mol Carcinog. 2013; 52(8):634-646.
23. Guo L, Xu J, Qi J, Zhang L, Wang J, Liang J, Qian N, Zhou H, Wei L and Deng L. MicroRNA-17-92a upregulation by estrogen leads to Bim targeting and inhibition of osteoblast apoptosis. J Cell Sci. 2013; 126(Pt 4):978-988.
24. Meyerson M and Pellman D. Cancer genomes evolve by pulverizing single chromosomes. Cell. 2011; 144(1):9-10.
25. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011; 144(1):27-40.
26. Feugeas O, Guriec N, Babin-Boilletot A, Marcellin L, Simon P, Babin S, Thyss A, Hofman P, Terrier P, Kalifa C, Brunat-Mentigny M, Patricot LM and Oberling F. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol. 1996; 14(2):467-472.
27. Araki N, Uchida A, Kimura T, Yoshikawa H, Aoki Y, Ueda T, Takai S, Miki T and Ono K. Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors. Clin Orthop Relat Res. 1991; (270):271-277.
28. Jin HY, Lai M and Xiao C. MicroRNA-17~92 is a powerful cancer driver and a therapeutic target. Cell Cycle. 2014; 13(4).